Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
Yonsei Medical Journal
;
: 990-998, 2011.
Article
in English
| WPRIM
| ID: wpr-30290
ABSTRACT
PURPOSE:
Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. MATERIALS ANDMETHODS:
Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4x107 DC were injected each time.RESULTS:
Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-gamma-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients.CONCLUSION:
In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Dendritic Cells
/
Enzyme-Linked Immunosorbent Assay
/
Monocytes
/
Treatment Outcome
/
Flow Cytometry
/
Immunotherapy
/
Melanoma
Type of study:
Practice guideline
Limits:
Humans
Language:
English
Journal:
Yonsei Medical Journal
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS